Zacks Research Issues Optimistic Forecast for UTHR Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Equities researchers at Zacks Research lifted their Q4 2024 EPS estimates for United Therapeutics in a research report issued to clients and investors on Tuesday, November 19th. Zacks Research analyst R. Department now expects that the biotechnology company will earn $6.04 per share for the quarter, up from their previous estimate of $5.40. The consensus estimate for United Therapeutics’ current full-year earnings is $25.10 per share. Zacks Research also issued estimates for United Therapeutics’ Q3 2025 earnings at $7.33 EPS, Q4 2025 earnings at $6.74 EPS, FY2025 earnings at $27.64 EPS, Q3 2026 earnings at $7.15 EPS and FY2026 earnings at $26.89 EPS.

Several other equities analysts also recently commented on the stock. Oppenheimer increased their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Jefferies Financial Group raised their price objective on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. The Goldman Sachs Group boosted their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. Wells Fargo & Company lifted their price target on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Finally, StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Trading Up 1.5 %

Shares of United Therapeutics stock opened at $372.89 on Friday. The company has a 50 day moving average of $365.06 and a 200-day moving average of $331.37. The company has a market cap of $16.65 billion, a PE ratio of 16.38, a price-to-earnings-growth ratio of 1.05 and a beta of 0.56. United Therapeutics has a 1-year low of $208.62 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter last year, the company posted $5.38 EPS. United Therapeutics’s quarterly revenue was up 22.9% compared to the same quarter last year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. ClariVest Asset Management LLC raised its position in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 42 shares during the last quarter. V Square Quantitative Management LLC bought a new stake in United Therapeutics in the 2nd quarter valued at $30,000. Innealta Capital LLC purchased a new stake in United Therapeutics in the 2nd quarter worth $33,000. USA Financial Formulas bought a new position in shares of United Therapeutics during the 3rd quarter valued at about $33,000. Finally, Brooklyn Investment Group purchased a new position in shares of United Therapeutics during the third quarter valued at about $33,000. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 7,802 shares of United Therapeutics stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the transaction, the chief financial officer now owns 3,210 shares of the company’s stock, valued at $1,108,766.10. The trade was a 70.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $45,293.30. This trade represents a 67.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 117,496 shares of company stock worth $43,765,042. Insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.